Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ: TSVT )

3.100 +0.450 (+16.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,423,280
Open 2.650
Bid (Size) 2.950 (2)
Ask (Size) 3.000 (1)
Prev. Close 2.650
Today's Range 2.600 - 3.115
52wk Range 1.535 - 15.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
From 2seventy bio, Inc.
Via Business Wire
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety

Performance

YTD
-66.63%
-66.63%
1 Month
+37.17%
+37.17%
3 Month
-29.22%
-29.22%
6 Month
-74.57%
-74.57%
1 Year
-77.19%
-77.19%

More News

Read More
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
Via Benzinga
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2seventy bio: Q3 Earnings Insights
Via Benzinga
Preview: 2seventy bio's Earnings
Via Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
3 Biotech Stocks With Key Catalysts Coming in December
Via InvestorPlace
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
The Latest Analyst Ratings for 2seventy bio
Via Benzinga
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
From 2seventy bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Via The Motley Fool
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023
Via Benzinga
Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
2seventy Bio's Cost Cuts Prudent But Analyst Says It Induces Lower Confidence In Lead Product
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
From 2seventy bio, Inc.
Via Business Wire
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
From 2seventy bio
Via Business Wire
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
From 2seventy bio, Inc.
Via Business Wire
Around $3.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.